- VYNE Therapeutics Inc VYNE announced that the first vitiligo patient had been dosed in a phase 1a/b study of VYN201, a locally administered, small molecule, pan-bromodomain and BET (extra-terminal domain) inhibitor for immunoinflammatory diseases.
- The clinical study is a first-in-human study designed to generate safety and pharmacokinetic data in healthy volunteers (phase 1a) and early clinical proof-of-concept data in vitiligo patients (phase 1b) to provide.
- The Company expects topline data for Phase 1a and Phase 1b portions of the study in the first half of 2023.
- In the Phase 1b portion, up to 30 patients with a clinical diagnosis of non-segmental vitiligo will receive VYN201 once daily in up to three dose cohorts.
- The primary objective of the Phase 1b portion of the study will be to evaluate the safety and pharmacokinetics of VYN201.
- The exploratory efficacy of VYN201 in patients with non-segmental vitiligo will also be evaluated, including pharmacodynamic biomarkers and photography.
- In August, VYNE Therapeutics announced results from the Phase 2a segment of a Phase 1b/2 study of FMX114 in mild to moderate atopic dermatitis (AD) that failed to meet the study’s primary endpoint disease severity index.
- Price promotion: VYNE shares are up 56.6% to $0.30 on Tuesday’s latest check.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
